About TargED
TargED is a company based in Utrecht (Netherlands) founded in 2020 by Marc Van Moorsel, Kristof Vercruysse, and Steven De Maat.. TargED has raised $82.85 million across 5 funding rounds from investors including Andera Partners, Hadean Ventures and Sunstone. TargED offers products and services including TGD001. TargED operates in a competitive market with competitors including ALX Oncology, Alpine Immune Sciences, Alector, Hummingbird Bioscience and Shattuck Labs, among others.
- Headquarter Utrecht, Netherlands
- Founders Marc Van Moorsel, Kristof Vercruysse, Steven De Maat
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Targed Biopharmaceuticals B.V.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$82.85 M (USD)
in 5 rounds
-
Latest Funding Round
$25.23 M (USD), Series A
Dec 18, 2025
-
Investors
Andera Partners
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TargED
TargED offers a comprehensive portfolio of products and services, including TGD001. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Biological compound for targeted breakdown of blood clots in thrombosis.
Funding Insights of TargED
TargED has successfully raised a total of $82.85M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $25.23 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $25.2M
-
First Round
First Round
(24 Nov 2020)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2025 | Amount | Series A - TargED | Valuation | BioGeneration Ventures | |
| Jul, 2025 | Amount | Series A - TargED | Valuation |
investors |
|
| Jul, 2025 | Amount | Grant - TargED | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TargED
TargED has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Andera Partners, Hadean Ventures and Sunstone. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Capital is provided to firms for growth, buyouts, and acquisitions.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investments are made by Sunstone in early-stage European companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TargED
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TargED
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Targed Comparisons
Competitors of TargED
TargED operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ALX Oncology, Alpine Immune Sciences, Alector, Hummingbird Bioscience and Shattuck Labs, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| domain | founded_year | HQ Location |
Immunotherapies for cancer treatment are developed via proprietary antibody platform.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Targed
Frequently Asked Questions about TargED
When was TargED founded?
TargED was founded in 2020.
Where is TargED located?
TargED is headquartered in Utrecht, Netherlands.
Who is the current CEO of TargED?
Kristof Vercruysse is the current CEO of TargED. They have also founded this company.
Is TargED a funded company?
TargED is a funded company, having raised a total of $82.85M across 5 funding rounds to date. The company's 1st funding round was a Series A of $11.79M, raised on Nov 24, 2020.
What does TargED do?
Developer of biological drugs for the treatment of thrombosis. The company offers its FDA-approved biological drugs and TargED Targeted Enzyme Delivery system which is a small antibody that can target the specific sites of thrombosis and enable the blood flow to reduce the risk for organ failure is reduced. The company target Thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS) and the lead compound Microlyse is a thrombolytic fusion protein that consisting two subunits i.e a nanobody domain targeting Von Willebrand Factor (VWF) which helps in wound healing also and the protease domain of the plasminogen activator urokinase. It targets the protease domain towards VWF, to active degradation of both VWF and fibrin.
Who are the top competitors of TargED?
TargED's top competitors include Alector, Hummingbird Bioscience and Alpine Immune Sciences.
What products or services does TargED offer?
TargED offers TGD001.
Who are TargED's investors?
TargED has 10 investors. Key investors include Andera Partners, Hadean Ventures, Sunstone, BioGeneration Ventures, and Utrecht Holdings Seed Fund.